Krystal Biotech, Inc. $KRYS Shares Purchased by Legal & General Group Plc

Legal & General Group Plc raised its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 2.8% during the second quarter, HoldingsChannel reports. The firm owned 68,393 shares of the company’s stock after purchasing an additional 1,884 shares during the period. Legal & General Group Plc’s holdings in Krystal Biotech were worth $9,401,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Geode Capital Management LLC raised its position in shares of Krystal Biotech by 1.2% in the second quarter. Geode Capital Management LLC now owns 619,547 shares of the company’s stock valued at $85,174,000 after buying an additional 7,194 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Krystal Biotech by 173.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company’s stock valued at $103,764,000 after acquiring an additional 365,304 shares during the last quarter. Braidwell LP raised its holdings in Krystal Biotech by 99.9% in the 1st quarter. Braidwell LP now owns 400,744 shares of the company’s stock valued at $72,254,000 after acquiring an additional 200,244 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Krystal Biotech by 3.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 250,514 shares of the company’s stock worth $45,168,000 after purchasing an additional 7,344 shares in the last quarter. Finally, Nuveen LLC acquired a new position in shares of Krystal Biotech during the 1st quarter worth approximately $42,223,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Stock Down 1.3%

Shares of Krystal Biotech stock opened at $215.11 on Tuesday. The firm has a market cap of $6.24 billion, a PE ratio of 32.25 and a beta of 0.48. Krystal Biotech, Inc. has a 52 week low of $122.80 and a 52 week high of $221.84. The business’s fifty day simple moving average is $193.27 and its 200-day simple moving average is $160.39.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, November 3rd. The company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $1.54. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. The firm had revenue of $97.80 million for the quarter, compared to analyst estimates of $93.72 million. As a group, equities analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Wall Street Analyst Weigh In

KRYS has been the subject of several recent research reports. Bank of America increased their price target on Krystal Biotech from $182.00 to $255.00 and gave the company a “buy” rating in a report on Friday, October 17th. Citigroup upped their target price on Krystal Biotech from $166.00 to $198.00 and gave the company a “neutral” rating in a report on Tuesday, November 4th. HC Wainwright reiterated a “buy” rating and set a $240.00 price target on shares of Krystal Biotech in a report on Monday, September 15th. Guggenheim set a $224.00 price target on shares of Krystal Biotech and gave the company a “buy” rating in a research report on Friday, October 17th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Krystal Biotech in a research report on Tuesday, November 25th. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, Krystal Biotech presently has a consensus rating of “Moderate Buy” and a consensus target price of $228.14.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).